ERBB2 and in situ carcinoma: Post‐IVT uCGP of these four patients revealed modest disease burdens composed of high‐risk mutation signatures, including TERT, TP53, and ERBB2 (Fig. 2D), consistent with the possibility of visually occult residual CIS.